QR-421a: Showing Benefits on One out of Four Usher Syndrome patients

Original article on AP News QR-421a showed early and encouraging evidence of activity, with 25% of patients showing a benefit across multiple concordant outcome measures and was well tolerated with no serious adverse events — QR-421a is the second ophthalmology program where clinical activity was predicted by translational models, further validating the platform — COVID-19 pandemic expected to impact timelines for the pipeline — ProQR anticipates its cash runway will fund operations into H2 2022 LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read

When touching is forbidden

When I was 18 years I was diagnosed with Usher Syndrome and it took me another eighteen years to understand which were the consequences of this disease and realize that it is one of the main causes of deaf blindness.
Read